Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 681 to 690 of 1584 total matches.
Capivasertib (Truqap) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
approved for use in those with AKT
pathway-altered tumors.
e33
The Medical Letter ® Vol. 66 Published ...
The oral kinase inhibitor capivasertib (Truqap –
AstraZeneca), a first-in-class AKT inhibitor, has
been approved by the FDA for use in combination
with the selective estrogen receptor degrader (SERD)
fulvestrant (Faslodex, and generics) for treatment of
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer in adults with
one or more PIK3CA/AKT1/PTEN-alterations who had
disease progression on at least one endocrine-based
regimen for metastatic disease or recurrence on or
within 12 months of completing...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e32-3 doi:10.58347/tml.2024.1696e | Show Introduction Hide Introduction
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
(steady state)
e37
The Medical Letter ® Vol. 66 Published online February 19, 2024
34.1 months. Among ...
The FDA has approved the oral tyrosine kinase
inhibitor repotrectinib (Augtyro – BMS) for treatment
of locally advanced or metastatic ROS1-positive
non-small cell lung cancer (NSCLC) in adults.
Repotrectinib is the third oral tyrosine kinase inhibitor
to be approved for this indication in the US; crizotinib
(Xalkori) and entrectinib (Rozlytrek) were approved
earlier.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e36-7 doi:10.58347/tml.2024.1696g | Show Introduction Hide Introduction
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
of MASH resolution with no worsening of fibrosis
The Medical Letter ® Vol. 66 (1701) April 29, 2024
66 ...
Resmetirom (Rezdiffra – Madrigal), a thyroid hormone
receptor-beta agonist, has received accelerated
approval from the FDA for treatment of noncirrhotic
nonalcoholic steatohepatitis (NASH) with moderate
to advanced fibrosis in adults. NASH has recently
been renamed metabolic dysfunction-associated
steatohepatitis (MASH). Resmetirom is the first drug
to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):65-6 doi:10.58347/tml.2024.1701a | Show Introduction Hide Introduction
Drugs for Assisted Reproduction
Treatment Guidelines from The Medical Letter • Oct 01, 2003 (Issue 14)
. (ISSN 1541-2784)
Vol. 1 (Issue 14) October 2003
Published by The Medical Letter, Inc.
1000 Main ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
acne, but it is teratogenic and has many adverse effects.
The Medical Letter ® Vol. 66 (1695) February ...
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20 doi:10.58347/tml.2024.1695a | Show Introduction Hide Introduction
Drugs for Parasitic Infections
Treatment Guidelines from The Medical Letter • Aug 01, 2013 (Issue 143)
: 800-211-2769
Treatment Guidelines from The Medical Letter • Vol. 11 (Suppl) • 2013 e1
AMEBIASIS ...
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians
anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most
parasitic infections.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
Letter ® Vol. 65 (1676) May 15, 2023
74
Table 1. Efficacy of Contraceptives for Pregnancy Prevention ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Drugs for Pneumonia
Treatment Guidelines from The Medical Letter • Sep 01, 2003 (Issue 13)
) is cultured in about 20% of cases (N
Sopena et al, Eur J Clin Microbiol Infect Dis 1999;
Vol. 1 (Issue 13 ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Drugs for Breast Cancer
Treatment Guidelines from The Medical Letter • Jan 01, 2005 (Issue 29)
Vol. 3 (Issue 29) January 2005
Published by The Medical Letter, Inc.
1000 Main Street ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Pharmaceutical Drug Overdose
Treatment Guidelines from The Medical Letter • Sep 01, 2006 (Issue 49)
or decreased motility.
4
Vol. 4 (Issue 49) September 2006
Published by The Medical Letter, Inc.
1000 ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
